In a report published Tuesday, Credit Suisse analyst Ralph Giacobbe upgraded the rating on LHC Group LHCG from Underperform to Outperform, and raised the price target from $22.00 to $32.00.
In the report, Credit Suisse noted, “Upgrading LHCG to Outperform (from Underperform), raising target price to $32 (from $22). Our 1st positive recommendation in Home Health since Dec 2008. 2015 an inflection for LHCG as: 1) payment pressure subsides, 2) regulatory backdrop improves, 3) cost savings accelerate, 4) deals mature and 5) under-levered balance sheet provides optionality.”
LHC Group closed on Monday at $25.38.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in